Document Detail

Antipsychotic drug use among nursing home residents taking rivastigmine.
MedLine Citation:
PMID:  16413429     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate whether or not rivastigmine use is associated with a decrease in the initiation of antipsychotic drug therapy among nursing home residents in the United States. METHODS: A retrospective analysis was performed using Minimum Data Set data and physician order files for newly admitted residents of 452 US nursing facilities from 2000 through 2002. The rivastigmine group included those who were diagnosed with Alzheimers disease (AD) and began rivastigmine treatment within 30 days of diagnosis. Patients were required to be on treatment for a minimum of 30 days. The control group included those who were diagnosed with AD, but did not receive a cholinesterase inhibitor. All subjects were antipsychotic drug-naive within 30 days of baseline (initiation of rivastigmine or initial AD diagnosis). A Cox proportional hazards model was used to estimate predicted risk of antipsychotic drug use. RESULTS: This study included 845 patients in the rivastigmine group and 517 patients in the control group. The rivastigmine group had fewer female patients, was younger, and had more verbal distress, sleep issues, sadness, loss of interest, and behavioral symptoms at baseline compared with the control group (P < .01). Overall initiation of antipsychotics was lower in the rivastigmine group (8.6%) compared with the control group (17.0%). Patients in the control group were almost 2 times more likely (relative risk = 1.86; P < .001) to take antipsychotics compared with patients taking rivastigmine, after adjusting for demographic covariates and mental health conditions or behavioral symptoms at baseline. Patients with baseline mental health conditions or behavioral symptoms were more likely to start antipsychotics than those without such conditions (P < .001). CONCLUSIONS: Study results suggest that nursing home residents with Alzheimers disease treated with rivastigmine have a reduced risk of initiating therapy with an antipsychotic drug compared with residents who do not receive cholinesterase inhibitor treatment.
Siva Narayanan; Kathleen M Beusterien; Simu K Thomas; Jonathan Musher; Bill Strunk
Related Documents :
25186259 - A self-management programme for copd: a randomised controlled trial.
17054149 - Zotepine for schizophrenia.
16139989 - Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical as...
15115949 - Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in f...
19302829 - Effects of the drd3 ser9gly polymorphism on aripiprazole efficacy in schizophrenic pati...
6140869 - Strategies for enhancing drug therapy of schizophrenia.
11676429 - Diagnosing and treating depression in the elderly.
21418069 - Mediating roles of adherence attitude and patient education on antidepressant use in pa...
11421499 - A review of long-term oxygen therapy for chronic obstructive pulmonary disease.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American Medical Directors Association     Volume:  7     ISSN:  1525-8610     ISO Abbreviation:  J Am Med Dir Assoc     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-01-17     Completed Date:  2006-06-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100893243     Medline TA:  J Am Med Dir Assoc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  12-6     Citation Subset:  IM    
Beverly Enterprises, Fort Smith, AR, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Alzheimer Disease / complications,  diagnosis,  drug therapy*
Analysis of Variance
Antipsychotic Agents / therapeutic use*
Chi-Square Distribution
Cholinesterase Inhibitors / therapeutic use*
Drug Utilization Review
Geriatric Assessment
Mental Disorders / etiology
Nursing Homes*
Phenylcarbamates / therapeutic use*
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Risk Factors
Sleep Disorders / etiology
Stress, Psychological / etiology
Treatment Outcome
United States
Reg. No./Substance:
0/Antipsychotic Agents; 0/Cholinesterase Inhibitors; 0/Phenylcarbamates; 123441-03-2/rivastigmine
Comment In:
J Am Med Dir Assoc. 2006 Jun;7(5):337-8   [PMID:  16765876 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Oral ddAVP for nighttime urinary incontinence in characterized nursing home residents: a pilot study...
Next Document:  Racial and socioeconomic differences in psychiatric symptoms in nursing home residents: a minimum da...